Clarity Pharmaceuticals Ltd: Notice of Annual General Meeting/Proxy Form
Clarity Pharmaceuticals Ltd: Cleansing Notice
Clarity Pharmaceuticals Ltd: Application for quotation of securities - CU6
Clarity Pharmaceuticals Ltd: Copper-67 SAR-bisPSMA updates
Clarity Pharmaceuticals Ltd: Positive guidance from the US FDA on Phase III trial
Clarity Pharmaceuticals Ltd: Michelle Parker Promoted to CEO
Clarity Pharmaceuticals Ltd: Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA
Clarity Pharmaceuticals Ltd: Change of Director's Interest Notices - AT CB CR TR MP
Clarity Pharmaceuticals Ltd: Cleansing Notice
Clarity Pharmaceuticals Ltd: Application for quotation of securities - CU6
Clarity Pharmaceuticals Ltd: COBRA study selected as a Top-Rated Oral Presentation
Clarity Pharmaceuticals Ltd: CORPORATE GOVERNANCE STATEMENT
Clarity Pharmaceuticals Ltd: Appendix 4G
Clarity Pharmaceuticals Ltd: Annual Report to shareholders
Clarity Pharmaceuticals Ltd: Ceasing to be a substantial holder
Clarity Pharmaceuticals Ltd: Notification regarding unquoted securities - CU6
Clarity Pharmaceuticals Ltd: Date of Annual General Meeting
Clarity Pharmaceuticals Ltd: Initial Director's Interest Notice - Parker
Clarity Pharmaceuticals Ltd: Appointment of Executive Director to Clarity's Board
Clarity Pharmaceuticals Ltd: Becoming a substantial holder
No Data
No Data